Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05691166

Reducing Falls With Progressive Resistance Training for the Oldest Old Adults With Sarcopenia

This study will investigate the effects of 12 months of high-intensity progressive resistance training compared with a control group on fall-rate in older adults with sarcopenia.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

80 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Circulation and Medical Imaging

Trondheim, 7491, Norway

About this study

Despite the wealth of theoretical benefits, existing literature on resistance training for falls prevention is not conclusive, given the sub-optimal resistance training paradigms, poor study quality, and use of multimodal training interventions, precluding isolation of the resistance training benefits. It is also possible that resistance training benefits for falls reduction will be most evident in those with sarcopenia to begin with as a risk factor for their falls. We will therefore conduct a randomised, controlled trial assessing the effects of resistance training reduce falls in the oldest old adults with sarcopenia, as well as to increase strength and muscle mass.

Amendment 2023-12-15: The description of the control condition was updated following ethics committee approval. Referral to the general practitioner for follow-up was replaced with provision of written information on current physical activity recommendations for older adults. This change was made to improve acceptability and feasibility of the control condition; the study outcomes and intervention were unchanged.

Amendments: 2024-09-18. We updated the low grip-strength inclusion criterion from [Men:<39.6kg, Women:<21.4kg] to [Men:<41.6kg, Women:23.4kg] based on normative values (Ref: Svinøy, O. E., Hilde, G., Bergland, A., & Strand, B. H. [2023]).

Extension amendment (2025-09-02): With new funding and ethics approval (REK 2022/462261), we added post-trial follow-up at 24 and 36 months to evaluate disability-free survival and the durability of effects on falls and several secondary outcomes. Falls during follow-up are collected via 12-month recall. No changes to interventions or the prespecified 0-12-month primary endpoints.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 80 years or older
  • Low muscular strength (grip strength: <41.3 kg for males and <23.4 kg for females [from 18.09.2024] or chair stand >15 seconds)
  • Community-dwelling incl. independent senior housing
  • Ambulatory without supervision or physical assistance from another person. Assistive devices such as canes/crutches/walkers allowed.
  • Able to see and hear sufficiently to undertake assessments and partake in the planned exercise training.

Exclusion criteria

  • Pre-existing diagnosis of dementia
  • Moderate or severe cognitive impairment (score <18 on the Mini-Mental State Examination)
  • Living in institutional care
  • Non-ambulatory or requiring person or wheelchair to assist when walking
  • Degenerative neurological and neuromuscular disease/disorder significantly influencing gait and mobility (e.g. amyotrophic lateral sclerosis [ALS] and Parkinson's disease).
  • Amputation (other than toes)
  • Contraindications to resistance training
  • Unstable fracture
  • Inability to comply with study requirements
  • Currently undertaking progressive resistance training

Treatment and study plan

High-intensity progressive resistance training

Behavioral

Supervised high-intensity progressive resistance training twice per week for 12 months

General practitioner care

Other

Referred to general practitioner (GP) for further follow-up. The GPs will be informed about participants sarcopenia status with results from assessments of muscle strength, muscle mass, and physical performance. The management of the sarcopenia is at the GPs own discretion.

Primary outcomes

  1. Falls

    Time frame: 12 months

    Relative risk for falls, fall rate per person years. Self-report.

Secondary outcomes

  1. Falls

    Time frame: 6 months

    Relative risk for falls, fall rate per person years. Self-report.

  2. Falls

    Time frame: 6, 12, 24, and 36 months.

    Number of falls, number of fallers/nonfallers/frequent fallers, and time to first fall. Self-report.

  3. Falls requiring medical attention

    Time frame: 6, 12, 24, 36 months

    Number of falls requiring medical attention. Collected via self-report and ascertained by linkage to the Norwegian Patient Registry and medical journals with the use of unique 11-digit Norwegian national identification number for each participant.

  4. Fall-related injuries

    Time frame: 6, 12, 24, 36 months

    Classified according to the International Classification of Diseases, 11th revision, classification system. Peripheral fracture rate per person-years, number of peripheral fractures, number of people sustaining peripheral fractures, and number of people sustaining multiple events. Collected via self-report and ascertained by linkage to the Norwegian Patient Registry and medical journals with the use of unique 11-digit Norwegian national identification number for each participant.

  5. Dynamic muscular strength

    Time frame: 6 and 12 months

    1-repetition maximum leg press and leg extension

  6. Grip strength

    Time frame: 6, 12, 24, 36 months

    Maximal isometric handgrip strength

  7. Muscular power

    Time frame: 6 and 12 months

    Muscular power assessed using a force platform installed on a leg press machine

  8. Physical performance

    Time frame: 6, 12, 24, 36 months

    Physical performance using the Short Physical Performance Battery

  9. Balance

    Time frame: 6, 12, 24, 36 months

    Static and dynamic balance using the Mini-Balance Evaluation Systems Test (BESTest)

  10. Stature

    Time frame: 6, 12, 24, 36 months

    Stretch stature using a wall-mounted stadiometer

  11. Body mass

    Time frame: 6, 12, 24, 36 months

    Body mass estimated using multi-frequency bioelectrical impedance analysis

  12. Body composition

    Time frame: 6, 12, 24, 36 months

    Estimated using multi-frequency bioelectrical impedance analysis. Fat mass, skeletal muscle mss, appendicular skeletal muscle mass.

  13. Circumferences

    Time frame: 6 and 12 months

    Waist, arm, and calf circumference

  14. Resting blood pressure and resting heart rate

    Time frame: 6, 12, 24, 36 months

    Systolic and diastolic blood pressure, and resting heart rate measured after 5 minutes of seated resting using an automated blood pressure device

  15. Orthostatic blood pressure

    Time frame: 6, 12, 24, 36 months

    Systolic and diastolic blood pressure response 1, and 3-min after standing up

  16. Physical activity

    Time frame: 6, 12, 24, 36 months

    Self-reported physical activity levels

  17. Health-related quality of life

    Time frame: 6, 12, 24, 36 months

    Health-related quality of life assessed using the 12-item Short-form health survey

  18. Fear of falling

    Time frame: 6, 12, 24, 36 months

    Fear of falling assessed using the Falls Efficacy Scale-International

  19. Cognitive function

    Time frame: 6 and 12 months

    Cognitive function evaluated using The Mini Mental State Examination

  20. Depression

    Time frame: 6, 12, 24, 36 months

    Levels of depression measured via the Geriatric Depression Scale.

  21. Frailty

    Time frame: 6, 12, 24, 36 months

    Physical frailty assessed according to Fried's frailty phenotype

  22. Nutritional status

    Time frame: 6, 12, 24, 36 months

    Nutritional status assessed using the Mini-nutritional Assessment Short form.

  23. Sleep quality

    Time frame: 6, 12, 24, 36 months

    Sleep quality assessed using the Pittsburgh Sleep Quality Index

  24. Hospital admissions

    Time frame: 0-12 months and 0-36 months

    Information about hospitalisations due to falls and fall-related injuries will be collected by means of electronic linkage to the Norwegian Patient Registry and medical journals with the use of a unique 11-digit Norwegian national identification number for each participant.

  25. Use of primary health care, community care, and assistive technology

    Time frame: 0-12 months and 0-36 months

    Use of primary health care (general practitioner, emergency room, physiotherapist, and chiropractor), community care, and assistive technology during the study will be collected by linkage to the Norwegian Municipal Patient and User Register (KPR) database with the use of a unique 11-digit Norwegian national identification number for each participant.

  26. Use of prescription drugs

    Time frame: 12 months

    Use of prescription drugs during the study will be collected by linkage to the Norwegian Prescribed Drug Registry with the use of a unique 11-digit Norwegian national identification number for each participant.

  27. Disability-free survival (DFS)

    Time frame: Baseline to 36 months post-randomisation

    DFS is defined as time from randomization to the first occurrence of: (i) death from any cause; (ii) incident dementia; or (iii) incident ADL disability. Participants with dementia or ADL disability at baseline are excluded from the DFS analysis.

    Death: ascertained by linkage to the Norwegian Cause of Death Registry.

    Incident ADL disability: score of 3-5 any of the six primary ADLs (Physical Self-Maintenance Scale) or a score of 0 for any of the five instrumental ADLs (Lawton IADL Scale). If ADL status cannot be obtained, admission to long-term nursing care (national registries) will be used as a proxy for disability.

    Incident dementia: registry/clinical diagnosis (ICD-10 F00-F03, G30, or equivalent codes in national registries). Exploratory supplement: MoCA assessed at 24/36 months; dementia defined as MoCA z-score ≤ -2.0 (age/education-adjusted).

  28. Healthcare and implementation costs

    Time frame: 0-12 months

    Intervention costs (resistance training and control), prescription medication, and health and care service utilisation during the 12-month intervention period. Costs for the training intervention include fitness centre membership fees and instructor labour costs (time worked + overheads). We will not consider potential travel costs for participants. We will obtain expenses related to prescription medication and health care service utilisation by linking participant data with data from the Norwegian Prescribed Drug Registry, the Norwegian Patient Registry (specialist health services), and the Municipal Patient and User Register (primary care, care services, physiotherapist, and chiropractor). We focus only on implementation costs, thus disregarding research protocol costs (e.g. recruitment).

  29. Quality-Adjusted Life-Years (QALY's)

    Time frame: 0-12 months

    We use the 12-item short-form health survey (SF-12) to assess health-related quality of life across eight areas, with scores summed into a physical component summary score and a mental component summary score, ranging from 0 to 100, with higher scores indicating a better quality of life.32 Next, we'll convert the SF-12 scores into SF-6D utility scores using the equation by Brazier and Roberts (2004).33 The utility scores range from 0 (equivalent to death) to 1 (equivalent to perfect health). Finally, we'll calculate QALYs for the 12-month intervention period by linearly interpolating SF-6D utility scores for baseline, six, and 12 months

Other outcomes

  1. Musculoskeletal pain

    Time frame: 6 and 12 months

    Musculoskeletal pain assessed using the "yes" or "no" question, "during the last year have you had pain in your muscles and/or joints that lasted for at least 3 consecutive months?". When answering "yes", participants will be asked to indicate the affected body areas. In addition, we will assess pain intensity for lower back and neck, specifically, using a 10-cm visual analogue scale (VAS).

  2. Changes in cardiac structure and function

    Time frame: 12 months

    Echocardiographic indices of atrial and ventricular structure and function

  3. Mortality

    Time frame: 0-12 and 0-36 months

    During the study unreported mortality will be assessed twice per year by linkage to the Norwegian population registry with the use of a unique 11-digit Norwegian national identification number for each participant.

  4. Cognitive function

    Time frame: 24 and 36 months

    Montreal Cognitive Assessment Tool

  5. Protein intake

    Time frame: 12, 24, 36 months

    Using the Protein Screener 55+

  6. Incremental cost-effectiveness ratio (ICER)

    Time frame: 0-12 months

    We will analyse the cost-effectiveness by estimating the Incremental Cost-Effectiveness Ratio (ICER) between the resistance training and control groups. We consider resistance training cost-effective if the ICER falls below the willingness-to-pay threshold (WTP).

Sponsors and collaborators

Lead sponsor

Norwegian University of Science and Technology

Other

Registry information

Official study title

Reducing Falls With Progressive Resistance Training (ReFit) for the Oldest Old Adults With Sarcopenia. A 12-month Randomised Controlled Trial (RCT).

Acronym: ReFit

Important dates

Study start
2023
Primary completion
2026
Study completion
2028
First posted
Jan 19, 2023
Registry last updated
Jan 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.